Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 2Completed 1Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 235Neoplasms 207Carcinoma, Non-Small-Cell Lung 101Colorectal Neoplasms 99Prostatic Neoplasms 93Lung Neoplasms 78Multiple Myeloma 53Melanoma 52Pancreatic Neoplasms 50Head and Neck Neoplasms 50Neoplasm Metastasis 48Leukemia, Myeloid, Acute 44Carcinoma, Hepatocellular 43Ovarian Neoplasms 39Brain Neoplasms 39Squamous Cell Carcinoma of Head and Neck 37Recurrence 37Glioblastoma 33Uterine Cervical Neoplasms 32Glioma 31Sarcoma 30Precursor Cell Lymphoblastic Leukemia-Lymphoma 29Stomach Neoplasms 28Lymphoma, Non-Hodgkin 28Lymphoma 27Colonic Neoplasms 27Carcinoma, Renal Cell 26Lymphoma, Follicular 25Esophageal Neoplasms 24Rectal Neoplasms 23

Interventions

Matrix-M 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Infectious Mononucleosis × 90 days × Clear all
NCT05683834 2026-04-22

Trial Evaluating the Immunogenicity and Safety of an Adjuvanted Epstein-Barr Virus (EBV) Glycoprotein 350 Vaccine in EBV-seronegative Persons

National Institutes of Health Clinical Center (CC)

Phase 1/2 Completed
25 enrolled

Herpes Simplex, Infectious Mononucleosis, Epstein-Barr Virus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡